SUTRO BIOPHARMA INC (STRO) — insider trading
Health Care · NASDAQ
Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for cancer treatment.
As of 2026-07-23, no SEC Form 4 insider transactions — open-market buys or sells, awards, or option exercises — have been reported for SUTRO BIOPHARMA INC (STRO) in our data.
We ingest insider filings from SEC EDGAR; a company can have no recent ownership filings, or its filings may not yet be in our data. You can always check the primary source directly via the SEC link above, or see the full company profile.
More on SUTRO BIOPHARMA INC: company profile · SEC filings · congressional trading · similar companies.
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR.